more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$6.87 USD

-0.10 (-1.43%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $6.86 -0.01 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

Top 38% (95 out of 252)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AxoGen (AXGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on August 06,2019

AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGNNegative Net Change

Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline

by Zacks Equity Research Published on July 30,2019

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGNNegative Net Change

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 08,2019

AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGNNegative Net Change

Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on May 01,2019

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGNNegative Net Change

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 13,2019

DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

medical

What's in Store for Humana (HUM) Stock in Q4 Earnings?

by Zacks Equity Research Published on February 04,2019

Higher enrollment and strong segmental results are expected to help Humana (HUM) in fourth-quarter earnings.

medical

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on October 29,2018

AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AXGNNegative Net Change

AxoGen (AXGN) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research Published on October 22,2018

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.